Handelsbanken Fonder’s Vaxcyte PCVX Stock Holding History

Handelsbanken Fonder’s Portfolio PCVX Stock Details PCVX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.87M	Buy	49,400 +8,500	+21%	+$462K	0.01%	682
2026 Q1	$2.38M	Hold	40,900	–	–	0.01%	673
2025 Q4	$1.89M	Sell	40,900 -4,100	-9%	-$183K	0.01%	760
2025 Q3	$1.62M	Buy	45,000 +10,100	+29%	+$335K	0.01%	815
2025 Q2	$1.14M	Hold	34,900	–	–	﹤0.01%	905
2025 Q1	$1.32M	Buy	34,900 +3,400	+11%	+$272K	0.01%	826
2024 Q4	$2.58M	Buy	31,500 +4,400	+16%	+$437K	0.01%	584
2024 Q3	$3.1M	Sell	27,100 -200	-0.7%	-$18K	0.01%	528
2024 Q2	$2.06M	Buy	27,300 +7,700	+39%	+$524K	0.01%	583
2024 Q1	$1.34M	Hold	19,600	–	–	0.01%	727
2023 Q4	$1.23M	Buy	19,600 +6,900	+54%	+$358K	0.01%	714
2023 Q3	$647K	Hold	12,700	–	–	﹤0.01%	930
2023 Q2	$634K	Buy	12,700 +2,400	+23%	+$114K	﹤0.01%	952
2023 Q1	$386K	Hold	10,300	–	–	﹤0.01%	1140
2022 Q4	$494K	Buy	+10,300	New	+$404K	﹤0.01%	966

Other funds holding PCVX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Jupiter Topco New York $245B AUM

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Handelsbanken Fonder's PCVX Position: Q2 2026 in Review

Handelsbanken Fonder increased its Vaxcyte (PCVX) stake by 21% in Q2 2026, buying an estimated $462K and bringing the position to 49,400 shares worth $2.87M. The position accounts for 0.01% of the portfolio, ranked #682.

Handelsbanken Fonder first reported a position in PCVX in Q4 2022 and has held it in 15 quarters since. The position peaked at $3.1M in Q3 2024. 331 funds tracked by Wall St. Rank hold PCVX as of Q2 2026.

Handelsbanken Fonder held 49,400 shares of Vaxcyte worth $2.87M as of Q2 2026.
Handelsbanken Fonder bought 8,500 Vaxcyte shares in Q2 2026, an estimated $462K.
Vaxcyte made up 0.01% of Handelsbanken Fonder's portfolio in Q2 2026, its #682 holding.
Handelsbanken Fonder first reported a position in Vaxcyte in Q4 2022 and has held it in 15 quarters since.
Handelsbanken Fonder's Vaxcyte position peaked at $3.1M in Q3 2024.
331 funds tracked by Wall St. Rank held Vaxcyte as of Q2 2026.

Based on Handelsbanken Fonder's 13F filing for Q2 2026, filed 10 Jul 2026.